Health & Biotech ASX Health Stocks: Firebrick skyrockets 80pc on Nasodine’s US launch April 17, 2024 Firebrick surged 80pc after launching Nasodine in the US. Next Science says it antimicrobial solution is effective. Melodiol unaudited revenue up 79% in Q1 FY24 April 17, 2024 Melodiol Global Health has generated $4.1 million in unaudited revenues for Q1 FY24, a 79% increase on the prior corresponding… Which ASX companies are resurrecting abandoned drugs? Part 2 April 17, 2024 ASX companies are cleverly resurrecting and repurposing abandoned drugs including LTR Pharma (ASX:LTR) with their erectile dysfunction spray. ASX Health Stocks: Island Pharma releases data on dengue fever drug, IDT signs $3m+ deal with Sanofi April 16, 2024 Island Pharma establishes dosage level for dengue fever drug. IDT signs deal with global French giant, Sanofi. Telix granted Fast… Bioxyne subsidiary granted upgraded wholesale licence for MDMA and psilocybin finished products April 16, 2024 Bioxyne says its wholly owned Breathe Life Sciences subsidiary has been granted an upgraded and amended wholesale licence for MDMA… Which ASX companies are resurrecting abandoned drugs? Part 1 April 16, 2024 Race Oncology (ASX:RAC) is among ASX-listed biotechs resurrecting or repurposing abandoned or underutilised drugs. ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer’s April 15, 2024 Atomo announces more purchase orders for HIV Self-Tests. Actinogen says first patient was treated in Alzheimer’s disease study. ASX Health Stocks: GTG to establish pilot program in US using its geneType Breast Cancer Risk Test April 11, 2024 Genetic Technologies to establish pilot programme in US. Imricor nabs sales in Croatia, AVITA Medical slumps after downgrading guidance. PharmAust inks approval from Macquarie University for Open-Label MND extension study April 10, 2024 Macquarie University has given PharmAust the green light to conduct an Open-Label extension study of monepantel (MPL) in patients with… Neurotech hits new milestone in Phase II/III autism trial after treating last patient April 10, 2024 Neurotech has treated the last patient in its Phase II/III NTIASD2 clinical trial for children with Autism Spectrum Disorder. The… Next» « Previous